Linagliptin: A novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus

Current Diabetes Reviews

Volumn 7, Issue 5, 2011, Pages 325-335

  Ghatak, Somsuvra B ^a   Patel, Devang S ^b   Shanker, Neeraj ^b   Srivastava, Ambrish ^b   Deshpande, Shrikalp S ^c   Panchal, Shital J ^a  

^a NIRMA UNIVERSITY   (India)

^b Torrent Research Centre   (India)

^c K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Dpp 4 inhibitors; Incretin; Linagliptin; Plasma glucose; Type ii diabetes mellitus

Indexed keywords

EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN; XANTHINE;

ARTICLE; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

EID: 80053530065     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911797415648     Document Type: Article

References (60)

1. Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol 2005; 5: 143-8.
2. Reimann M, Bonifacio E, Solimena M, et al. An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther 2009; 121: 317-31.
3. Jain S, Saraf S. Type 2 diabetes mellitus-Its global prevalence and therapeutic strategies. Diabet Metab Syndr: Clin Res Rev 2010; 4: 48-56.
4. Seshadri KG, Kirubha MHB. Gliptins: A new class of oral antidiabetic agents. Indian J Pharm Sci 2009; 71: 608-14.
5. Hinnen D, Nielsen LL, Waninger A, et al. Incretin mimetics and DPP-IV Inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006; 19: 612-20.
6. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209.
7. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non- insulin-dependent diabetes mellitus. J Diabetes Complicat 1998; 12: 110-9.
8. Panunti B, Jawa AA, Fonseca VA. Mechanisms and therapeutic targets in type 2 diabetes mellitus. Drug Discov Today Dis Mech 2004; 1: 151-7.
9. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 Inhibitor for the treatment of type 2 diabetes mellitus. Adv Thera 2009; 26: 249-62.
10. Patel DS, Deshpande SS, Pathak KY, Rajesh V. Saxagliptin: a molecule for treatment of type II diabetes mellitus. Clin Res 2009; 1: 50-7.
11. Munro NM, Levy JC. Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes. Prim Care Diabetes 2007; 1: 103-5.
12. Holst JJ, Orskov C. The incretin approach for diabetes treatment modulation of islet hormone release by GLP-1 agonism. Diabetes 2004; 53: S197-S204.
13. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34: S251-7.
14. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23.
15. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-13.
16. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-87.
17. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485-93.
18. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 2004; 4: 589-96.
19. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007; 21: 517-33.
20. Madsbad S. Treatment of type 2 diabetes with incretin based therapies. Lancet 2009; 373: 438-9.
21. McIntosh CHS, Demuth HU, Kim SJ, et al. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol 2006; 38: 860-72.
22. Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs 2008; 11: 906-17.
23. Larsen J, Hylleberg B, Ng K, et al. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-21.
24. Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 2009; 17: 1783-802.
25. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 2006; 38: 831-44.
26. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-78.
27. Spiriva, Micardis and Flomax - Boehringer Ingelheim's highly successful products show good growth. Excellent progress in research and development. Strong Euro curbs growth. Expenditure in R&D+M reduces operating income. Boehringer Ingelheim Corp PRESS RELEASE 2008 August 07.
28. Boehringer Ingelheim Unveils Diabetes Pipeline. Boehringer Ingelheim Corp PRESS RELEASE 2009 June 09. Available from: http://www.boehringeringelheim.ca/en/Home/News_Centre/news_detail.jsp?paramOid=3267 [Accessed 18 May 2011].
29. http://clinicaltrials.gov/ct2/results?term=linagliptin [Accessed 18 May 2011].
30. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin- 1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50: 6450-3.
31. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-82.
32. Thomas L, Himmelsbach F, Eckhardt M, Langkopf E, Mark M. BI 1356, a novel and selective xanthine based DPP-IV inhibitor, exhibits a superior profile when compared to sitagliptin and vildagliptin. Diabetologia 2007; 50: Abs 0879.
33. Himmelsbach F, Dugi K, Eckhardt M, et al. Discovery of BI 1356: a highly potent and long-acting DPP-IV inhibitor with a xanthine scaffold. Am Chem Soc Natl Meet Exposition 2007; 234: Medi-24.
34. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin- 1-yl)-7-but-2-ynyl-3-methyl-1-(4 methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-63.
35. Linke A, Frank S, Mark M, Klein T. The DPP-4 inhibitor linagliptin (BI 1356) improves wound healing in ob/ob mice [abstract]. Diabetes 2009; 58: A161.
36. 2nd International Boehringer Ingelheim Research & Development press conference. Boehringer Ingelheim Corp Company Presentation 2008 October 17.
37. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009; 61: 55-62.
38. Heise T, Graefe-Mody EU, Huettner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009; 1: 786-94.
39. Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008; 48: 1171-8.
40. Dittberner S, Duval V, Staab A, Troconiz I, Graefe-Mody EU, Jaehde U. Determination of the absolute bioavailability of BI 1356, a substance with non-linear pharmacokinetics, using a population pharmacokinetic modelling approach. [abstract 1110]. Poster presented at the 16th Annual Meeting of the Population Approach Group in Europe, June 2007, København, Denmark. Available from: www.page-meeting.org/?abstract=1110.
41. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-7.
42. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
43. Huettner S, Graefe-Mody EU, Ring A, Ritzhaupt A, Dugi KA. BI 1356, a novel and selective xanthine based DPP-IV inhibitor, demonstrates good safety and tolerability with a wide therapeutic window. Diabetes 2007; 56: Abs 0586-P.
44. Sesoko S, Nakajima M, Hayashi N, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of the dipeptidyl peptidase 4 inhibitor BI 1356 (linagliptin) in healthy Japanese volunteers [abstract]. Diabetes 2008; 57: A159.
45. Kanada S, Watada H, Hayashi N, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of BI 1356 (linagliptin), a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetes [abstract]. Diabetes 2008; 57: A158.
46. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 542-50.
47. Uhlig-Laske B, Ring A, Graefe-Mody EU, et al. DPP-4 inhibitor linagliptin improves glycemic control in type 2 diabetic patients when added to ongoing metformin therapy [abstract]. Diabetes 2009; 58: A143.
48. Owens DR, Swallow R, Woerle HJ, et al. Linagliptin improves glycemic control in type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain and low risk of hypoglycaemia. Poster No 548-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, U.S.A.
49. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
50. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-67.
51. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabetes, Obes Metab 2011; 13(7): 653-61.
52. Kawamori R, Inagaki N, Araki E, et al. Linagliptin provides superior glycemic control compared to voglibose as monotherapy in Japanese patients with Type 2 diabetes. Poster No 632-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA.
53. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Poster number 696-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA.
54. Barnett AH, Harper R, Toorawa R, et al. Linagliptin monotherapy improves glycemic control in type 2 diabetes patients for whom metformin therapy is inappropriate. Poster no. 823-P, 46th European Association for the Study of Diabetes Annual Meeting, September 2010, Stockholm, Sweden.
55. Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Poster no. 821-P, 46th European Association for the Study of Diabetes Annual Meeting, September 2010, Stockholm, Sweden.
56. Graefe-Mody U, Friedrich C, Port A, et al. Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment. Poster no. 822-P, 46th European Association for the Study of Diabetes Annual Meeting, September 2010, Stockholm, Sweden.
57. Eckhardt M, Hauel N, Himmelsbach F, et al. 3,5-Dihydroimidazo[ 4,5-d] pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg Med Chem Lett 2008; 18: 3158-62.
58. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009; 25: 1963-72.
59. Graefe-Mody EU, Friedrich C, Jungnik A, Dugi KA. Lack of pharmacokinetic interactions between the novel DPP-4 inhibitor linagliptin (BI 1356) and pioglitazone in healthy subjects [abstract 13]. Poster presented at 38th Annual Meeting of the American College of Clinical Pharmacology, San Antonio, September 2009.
60. Tradjenta™ (linagliptin) tablets. Highlights of prescribing information. Initial U.S. Approval: 2011.